

BRETT GUTHRIE, KENTUCKY  
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY  
RANKING MEMBER

ONE HUNDRED NINETEENTH CONGRESS

# Congress of the United States

## House of Representatives

### COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6115

Majority (202) 225-3641

Minority (202) 225-2927

August 13, 2025

John C. Magee, MD  
President  
Organ Procurement & Transplantation Network Board of Directors  
UH South Rm 6689 - SPC 5296  
1500 East Medical Center Drive  
Ann Arbor, Michigan 48109

Dear Dr. Magee,

Thank you for appearing before the Subcommittee on Oversight and Investigations on Tuesday, July 22, 2025, to testify at the hearing entitled "Ensuring Patient Safety: Oversight of the U.S. Organ Procurement and Transplant System."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Wednesday, August 27, 2025. Your responses should be mailed to Annabelle Huffman, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed to [Annabelle.Huffman@mail.house.gov](mailto:Annabelle.Huffman@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

A handwritten signature in blue ink that reads "John Joyce". The signature is fluid and cursive, with the first and last names clearly distinguishable.

John Joyce, M.D.

Chairman

Subcommittee on Oversight and Investigations

Committee on Energy and Commerce

cc: Yvette Clarke, Ranking Member, Subcommittee on Oversight and Investigations

Attachment

## **Additional Questions for the Record**

### **The Honorable John Joyce, M.D. (R-PA)**

1. As the current President of OPTN's Board of Directors, how do you view your role in ensuring more transparency and accountability in the future?
2. What concerns you most about the underreporting of incidents related to patient safety?
  - a. Do you think that improvements can be made to foster a culture in which people feel more comfortable reporting concerns and confident that reports they make to the OPTN will be taken seriously?
    - i. If so, what improvements do you recommend?

### **The Honorable Frank Pallone, Jr. (D-NJ)**

1. What is the current status of the OPTN Board of Directors' development of a systemwide policy outlining the steps to follow to pause a donation after circulatory death (DCD) protocol as directed in HRSA's Corrective Action Plan?
  - a. By what date does the OPTN Board expect to submit its proposed policy to HRSA?
2. How do you plan to work with HRSA to make sure that the OPTN and HRSA are working collaboratively to improve oversight and accountability?
  - a. How do you and the new OPTN Board of Directors plan to conduct constructive oversight of OPOs and other OPTN members?
  - b. Is the OPTN Board considering reforms to the Membership and Professional Standards Committee (MPSC) to strengthen future OPTN oversight?
3. How will the OPTN Board of Directors ensure that any entity involved in future patient safety investigations is transparent and thorough in its responses to inquiries related to the investigation?